Related Experiment Video
Updated: May 15, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
[Clinicopathologic and cytogenetic features of 114 Chinese mantle cell lymphoma cases]
Min Li1, Xiao-Yan Wang, Xue-Min Xue
1Department of Pathology, Peking University, HSC, Beijing, China.
Insights
Chinese mantle cell lymphoma (MCL) predominantly affects older males, often involving lymph nodes and bone marrow. High Ki-67 expression indicates a poor prognosis, while Rituximab may improve survival in MCL patients.
Area of Science:
- Hematopathology
- Oncology
- Genetics
Context:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with diverse clinical presentations.
- Understanding the clinicopathologic and cytogenetic features of MCL in specific populations, such as Chinese patients, is crucial for diagnosis and treatment.
- Previous studies have highlighted the importance of genetic alterations like CCND1 rearrangements in MCL pathogenesis.
Purpose:
- To delineate the clinicopathologic characteristics, immunophenotype, and cytogenetic profile of Chinese patients diagnosed with mantle cell lymphoma (MCL).
- To evaluate the prognostic significance of Ki-67 expression and the therapeutic impact of Rituximab in this cohort.
- To identify common genetic abnormalities, specifically CCND1 gene alterations, in Chinese MCL cases.
Summary:
- This study analyzed 114 Chinese MCL cases, revealing a predilection for older males, with common involvement of lymph nodes and bone marrow.
- Immunohistochemistry showed high expression of CD20, CD79a, PAX5, and cyclin D1, consistent with MCL. CCND1 gene alterations were frequent (80%).
- High Ki-67 expression ( > 40%) was associated with shorter median survival (36 months vs. 57 months, P=0.003), and Rituximab showed a trend towards improved outcomes.
Impact:
- This research provides valuable insights into the specific features of MCL in the Chinese population, aiding in more accurate diagnosis and risk stratification.
- The findings underscore the prognostic value of Ki-67 and suggest that Rituximab-based therapies may enhance survival for Chinese MCL patients.
- Identifying CCND1 gene alterations as the most common cytogenetic abnormality reinforces its role in MCL pathogenesis and potential as a therapeutic target.
Objective:
To study the clinicopathologic features, immunotype and cytogenetics of Chinese mantle cell lymphoma (MCL).
Methods:
114 MCL cases were collected from hematopathology lab of department of pathology, Peking University, HSC. Routine HE stain and immune stain were used to investigate the clinicopathologic features and immune type. Breaks of CCND1 and IgH/CCND1 fusion genes were detected by FISH.
Results:
The ratio of male to female was 3.56:1 (89:25) with the median age of 60 years old (20 - 83 years old). 78 cases (68.42%, 78/114) primarily showed lymph node involvement, including 49 cases (49/78, 62.82%) jugular node involvement; 36 cases (31.58%, 36/114) showed extra-nodal involvement. 23 cases (23/114, 20.18%)showed bone marrow involvement. The expressions of CD3ε, CD20, CD79a, PAX5, CD5, cyclinD1 and Bcl-2 were 0% (0/114), 99.12% (113/114), 96.43% (27/28), 97.56% (40/41), 67.89% (74/109), 100% (114/114) and 94.12% (48/51), respectively. Break of CCND1 gene was found in 20 cases (80%, 20/25), the fusion gene of IgH-CCND1 in 16 cases (80%, 16/20), the break of IgH gene in 9 cases (100%, 9/9)and its fusion gene in 8 cases (88.89%, 8/9). We followed up 75 cases with a period of 2-57 months. The median survival was 40.78 months. The survivals at 1 year, 2 year and 3 year were 84.13% (53/63), 68.09% (32/47) and 37.5% (12/32), respectively. The median survival of group with more than 40% expression of Ki-67 was 36 months, the group with less than 40% expression of Ki67 57 months (P = 0.003). 7 of 13 patients accepted Rituximab plus traditional chemotherapy attained CR, 3 cases PR. 11 of 44 cases accepted traditional chemotherapy attained CR, 9 cases PR (P = 0.052).
Conclusion:
Most of Chinese MCL occurred in older male, multi-lymphadenopathy and bone marrow involvement were common in MCL as a aggressive tumor. High expression of Ki-67 was an adverse prognostic indicator. Rituximab could improve the survival. Change of CCND1 gene was the most common cytogenetic abnormality.
